Breaking News
Investing Pro 0
Cyber Monday SALE: Up to 54% OFF InvestingPro+ CLAIM OFFER

Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'

Coronavirus Apr 29, 2020 10:05PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California 2/2
 
GILD
+0.98%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Deena Beasley and Manas Mishra

(Reuters) - The top U.S. infectious disease official said Gilead Sciences Inc 's experimental antiviral drug remdesivir will become the standard of care for COVID-19 after early clinical trial results on Wednesday showed it helped patients recover more quickly from the illness caused by the coronavirus.

Preliminary results from a U.S. government trial showing that patients given remdesivir recovered 31% faster than those given a placebo, were hailed by Dr. Anthony Fauci as "highly significant."

"This is really quite important," Fauci told reporters at the White House, likening it to a moment in 1986 "when we were struggling for drugs for HIV and we had nothing."

"This will be the standard of care," he said.

The U.S. Food and Drug Administration said it has been in discussions with Gilead (O:GILD) about making remdesivir available to patients as quickly as possible, but the agency declined to comment on any plans to grant the drug regulatory approval.

"I want them to go as quickly as they can," President Donald Trump said, when asked if he wanted the FDA to grant emergency use authorization for remdesivir. "We want everything to be safe, but we would like to see very quick approvals, especially with things that work."

The closely watched drug, given by intravenous infusion to hospitalized patients, has moved markets in the past few weeks following the release of data from several studies that painted a mixed picture of its effectiveness, and Fauci cautioned that the latest data still needs to be analyzed.

Gilead's shares rose more than 5% on Wednesday to close at $83.14 and are up 27% so far this year.

Interest in remdesivir has been high as there are no approved treatments or preventive vaccines for COVID-19, and doctors are desperate for anything that might alter the course of the disease that attacks the lungs and can shut down other organs in severe cases.

Doctors have been eager for results from the NIH study because it is a large trial in which patients were randomized to treatment with the drug or a placebo without participants or doctors knowing which group they were in - the gold standard for clinical trials.

Gilead earlier this month said it was prepared to donate to hospitals its existing supply of 1.5 million doses of remdesivir, which it said was enough for more than 140,000 patients, although that number would increase if the drug could be given for a shorter duration. Regulatory approval of the drug would clear the way for commercial sales.

"We are working to build a global consortium of pharmaceutical and chemical manufacturers to expand global capacity and production," Gilead Chief Executive Daniel O'Day said in an open letter on Wednesday.

He also said Gilead is looking at ways to potentially bring the treatment to a broader patient population by investigating other formulations and means of delivery.

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, said partial results from its 1,063-patient trial show that hospitalized COVID-19 patients given remdesivir recovered in 11 days, compared to 15 days for patients given a placebo.

The study showed a trend toward better survival for remdesivir - 8% of patients given the drug died compared with 11.6% in the placebo group - but the difference was not statistically significant so may not be due to Gilead's drug.

The trial's lead researcher told Reuters on Friday that full results could come by mid-May.

"The full dataset will provide more clarity on how remdesivir can best be used," said Dr. Aneesh Mehta, a researcher on the NIH trial from Emory University School of Medicine in Atlanta.

'GLIMMER OF HOPE'

Despite the excitement, Dr. Lawrence K. Altman, global fellow at The Wilson Center in Washington, DC, was not ready to celebrate the preliminary findings.

The new data "offers a glimmer of hope" that remdesivir has an effect against COVID-19, but more scientific analysis is needed "comparing them to other studies of the drug that have shown mixed results," he said in a statement.

Also on Wednesday, results were published by the Lancet medical journal of a trial conducted in China that concluded remdesivir failed to improve patients’ condition or reduce the pathogen’s presence in the bloodstream. Gilead said previously that those findings were inconclusive because the study was terminated early.

"The drug seems to have antiviral activity - how much is as yet unclear," Dr. Daniel McQuillen, an infectious disease specialist at Lahey Hospital & Medical Center in Burlington, Massachusetts, told Reuters. "Seems likely that it might need use with another antiviral agent."

Combination antiviral treatments have proven highly effective against other diseases.

Gilead also provided data on a study in severe COVID-19 patients it has conducted in dozens of medical centers, which does not have a placebo comparison but tested the drug under five-day and 10-day regimens.

In that 397-patient trial, Gilead said clinical improvements were similar regardlesss of treatment duration, and patients treated early on with remdesivir did better than patients who were treated later in the course of infection.

Remdesivir, which previously failed as a treatment for Ebola, is being tried against COVID-19 because it is designed to disable the mechanism by which certain viruses make copies of themselves and potentially overwhelm their host's immune system.

The company is also studying the drug in patients with less severe COVID-19, but those results are not expected until later next month.

 

Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (41)
Steven Francis
Steven Francis Apr 30, 2020 12:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
So hydroxychloroquine get some low budget observational non randomized trial analysis done by doctors under emergency situations with patients in unknown states of progression while this drug gets a randomized clinical trial to be pushed thru at lighteningvspeed. Sounds like the FDA is pickinggood ole boy favorites while people are dying. Utterly corrupt doesn't begin to describe this cesspool of a nation.
Yous Bou
Yous Bou Apr 29, 2020 12:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I m really outraged, how people with no scientific background, seating comfortably in their chairs and commenting on scientific matter, if you are in ICU you will take a 5% cure chance if you can afford it, so we are talking about lives despite what value this product may bring back to you. so show some respect.
Lysander Kutsara
Lysander Kutsara Apr 29, 2020 12:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Disrespect is a personal matter and doesn't apply when commenting on the macro effect of any treatment. No one here has been disrespectful of anyone who deserves our respect, and Fauci, acting like a fascism is the answer to heath and medical issues is not deserving.
DONGHUN LEE
DONGHUN LEE Apr 29, 2020 12:04PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Poor Results. 85-88% of patients are discharged without any treatment.
Pradeep Kannaiah
Pradeep Kannaiah Apr 29, 2020 11:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fake. Marketing gimmick
known un
known un Apr 29, 2020 11:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
My mom's delicious meal was also effective in relieving Corona symptoms, and I think vitamins are also effective in Corona, and if you count it like that, what is it that is not effective?
Kaveh Sun
Kaveh Sun Apr 29, 2020 11:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Not effective if u r hospitalized. This drug is tested on people who r in hospitals.
Kaveh Sun
Kaveh Sun Apr 29, 2020 11:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Less 5% go to the hospital, the rest get over without any treatment.
Max Vivcharyk
Max Vivcharyk Apr 29, 2020 11:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Tylenol also improve symptoms.
Luciano Rioja
Luciano Rioja Apr 29, 2020 10:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Early means. After someone get infected? So better take it to prevent. These treatment wont work Is fake
Kaveh Sun
Kaveh Sun Apr 29, 2020 10:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
improvement is measured with a scoring system ranging from hospital discharge (loest score) to death (highest score). 68% improvement compare to placebo
Kaveh Sun
Kaveh Sun Apr 29, 2020 10:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gilead website, Among those hospitalized who received the drugs early, 68% improved ( compare to those without ). Aapprox less than 5% of people who have the coronavirus r hospitalized.
Steve Bucher
Steve Bucher Apr 29, 2020 10:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Shell game with numbers. No real proof of effectiveness. This is being kept propped up and will soon crash.
Edward Chong
Edward Chong Apr 29, 2020 10:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
then dont buy. wait for next year to crash ok.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email